Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression.
TILs
breast cancer
computational pathology
machine learning
risk of recurrence
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Apr 2022
26 Apr 2022
Historique:
received:
17
03
2022
revised:
09
04
2022
accepted:
15
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
Tumor-infiltrating lymphocytes (TILs) have been established as a robust prognostic biomarker in breast cancer, with emerging utility in predicting treatment response in the adjuvant and neoadjuvant settings. In this study, the role of TILs in predicting overall survival and progression-free interval was evaluated in two independent cohorts of breast cancer from the Cancer Genome Atlas (TCGA BRCA) and the Carolina Breast Cancer Study (UNC CBCS). We utilized machine learning and computer vision algorithms to characterize TIL infiltrates in digital whole-slide images (WSIs) of breast cancer stained with hematoxylin and eosin (H&E). Multiple parameters were used to characterize the global abundance and spatial features of TIL infiltrates. Univariate and multivariate analyses show that large aggregates of peritumoral and intratumoral TILs (forests) were associated with longer survival, whereas the absence of intratumoral TILs (deserts) is associated with increased risk of recurrence. Patients with two or more high-risk spatial features were associated with significantly shorter progression-free interval (PFI). This study demonstrates the practical utility of Pathomics in evaluating the clinical significance of the abundance and spatial patterns of distribution of TIL infiltrates as important biomarkers in breast cancer.
Identifiants
pubmed: 35565277
pii: cancers14092148
doi: 10.3390/cancers14092148
pmc: PMC9105398
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : U24CA215109
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA016086
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008444
Pays : United States
Organisme : NCI NIH HHS
ID : NIH/NCI P50-CA58223
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA058223
Pays : United States
Organisme : NCI NIH HHS
ID : UH3CA225021
Pays : United States
Organisme : NCI NIH HHS
ID : P01CA151135
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA257388
Pays : United States
Références
Adv Cancer Res. 2019;143:295-349
pubmed: 31202361
Nat Med. 2020 Jul;26(7):1054-1062
pubmed: 32461698
Front Oncol. 2017 Aug 03;7:156
pubmed: 28824872
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
Breast. 2004 Aug;13(4):272-5
pubmed: 15325660
J Natl Cancer Inst. 2018 Feb 1;110(2):
pubmed: 28859290
Cancers (Basel). 2019 Nov 20;11(12):
pubmed: 31756919
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Cancer Immunol Res. 2015 Aug;3(8):827-35
pubmed: 26242760
Br J Cancer. 2013 Sep 17;109(6):1618-24
pubmed: 23963148
Br Med J. 1957 Apr 6;1(5022):779-86
pubmed: 13404306
J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
pubmed: 16106022
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Ann Oncol. 2014 Mar;25(3):611-618
pubmed: 24401929
NPJ Breast Cancer. 2021 Dec 1;7(1):150
pubmed: 34853355
Front Oncol. 2022 Feb 16;11:806603
pubmed: 35251953
Am J Physiol Cell Physiol. 2021 May 1;320(5):C750-C760
pubmed: 33657326
NPJ Breast Cancer. 2020 May 12;6:16
pubmed: 32411818
Semin Cancer Biol. 2018 Oct;52(Pt 2):178-188
pubmed: 29104025
Ecancermedicalscience. 2019 Apr 24;13:924
pubmed: 31281421
JAMA Oncol. 2017 Dec 1;3(12):1654-1662
pubmed: 28472234
Front Immunol. 2017 Dec 19;8:1830
pubmed: 29312327
Curr Opin Immunol. 2013 Apr;25(2):261-7
pubmed: 23579076
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Breast Care (Basel). 2019 Apr;14(2):103-110
pubmed: 31798382
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Breast Cancer Res. 2017 Dec 11;19(1):131
pubmed: 29228969
Breast Cancer. 2017 Jan;24(1):3-15
pubmed: 27138387
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Cancers (Basel). 2021 Jun 18;13(12):
pubmed: 34207414
Cancer Metastasis Rev. 2011 Mar;30(1):5-12
pubmed: 21249426
Cancer Invest. 2008 Dec;26(10):1024-31
pubmed: 19093260
J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52
pubmed: 19815849
NPJ Breast Cancer. 2020 May 12;6:17
pubmed: 32411819
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Med Oncol. 2018 Jan 31;35(3):25
pubmed: 29388007
J Immunother. 2010 May;33(4):335-51
pubmed: 20386472
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
Arch Otolaryngol Head Neck Surg. 2000 Nov;126(11):1329-32
pubmed: 11074829
Proc SPIE Int Soc Opt Eng. 2019 Feb;10956:
pubmed: 31997849
Br J Cancer. 2013 Nov 12;109(10):2705-13
pubmed: 24129232
J Pathol. 2017 Feb;241(3):375-391
pubmed: 27861902
Clin Cancer Res. 2020 Feb 1;26(3):738-745
pubmed: 31653641
Cancer Res. 2007 Mar 1;67(5):1883-6
pubmed: 17332313
Med Image Anal. 2019 Dec;58:101563
pubmed: 31561183
Br J Cancer. 2012 Aug 21;107(5):864-73
pubmed: 22878371
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1784-1791
pubmed: 31395590
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
PLoS One. 2019 Jan 25;14(1):e0211488
pubmed: 30682163
Clin Orthop Relat Res. 1991 Jan;(262):3-11
pubmed: 1984929
J Pathol Inform. 2021 Nov 15;12:45
pubmed: 34881099
Anticancer Res. 2014 Mar;34(3):1115-25
pubmed: 24596349
N Engl J Med. 2005 Dec 22;353(25):2654-66
pubmed: 16371631
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
BMC Cancer. 2020 Nov 25;20(1):1150
pubmed: 33238978
JCI Insight. 2019 Aug 13;5:
pubmed: 31408436
Cancer Res. 1998 Aug 15;58(16):3491-4
pubmed: 9721846
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Immunity. 2013 Jul 25;39(1):11-26
pubmed: 23890060
Am J Pathol. 2020 Jul;190(7):1491-1504
pubmed: 32277893
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Breast Cancer Res. 2019 Dec 26;21(1):151
pubmed: 31878981
Clin Transl Oncol. 2016 May;18(5):497-506
pubmed: 26459255
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
JAMA Oncol. 2017 Dec 1;3(12):1707-1711
pubmed: 28750120
Histopathology. 2020 Aug;77(2):181-185
pubmed: 32056259
Immunity. 2020 Jan 14;52(1):55-81
pubmed: 31940273
Oncoimmunology. 2018 Jul 30;7(10):e1490854
pubmed: 30386679
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
iScience. 2021 Apr 03;24(5):102394
pubmed: 33997679
Ann Oncol. 2021 Oct;32(10):1236-1244
pubmed: 34311075
Cancer. 1949 Jul;2(4):635-42
pubmed: 18144972
Cancers (Basel). 2021 Aug 31;13(17):
pubmed: 34503219
Breast Cancer Res Treat. 2020 Jan;179(1):185-195
pubmed: 31535320
Nat Cancer. 2021 Aug;2(8):794-802
pubmed: 35118423
Cell Rep. 2018 Apr 3;23(1):181-193.e7
pubmed: 29617659
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41
pubmed: 26667975
Ann Oncol. 2019 Feb 1;30(2):236-242
pubmed: 30590484
Breast Cancer Res. 2020 May 14;22(1):47
pubmed: 32408905
JAMA. 2006 Jun 7;295(21):2492-502
pubmed: 16757721
Breast Cancer Res Treat. 2015 Nov;154(1):145-54
pubmed: 26458823
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Bioinformatics. 2019 Sep 15;35(18):3461-3467
pubmed: 30726865
NPJ Breast Cancer. 2021 Jan 21;7(1):6
pubmed: 33479248
Cancer. 1996 Apr 1;77(7):1303-10
pubmed: 8608507